CARB-X

CARB-X is excited to welcome its newest funder! The Government of #Italy announced a commitment of US$21 million over the next three years to CARB-X at the G7 Joint Finance Health and Ministers’ Meeting last week. New funding from Italy will enhance CARB-X’s efforts to support, accelerate, and coordinate the early-stage development of innovative products aimed at preventing, diagnosing, and treating drug-resistant bacterial infections, a leading cause of death around the world, particularly in low- and middle-income countries (LMICs). “We are profoundly grateful to the Italian Government for their generous support,” said Kevin Outterson, Executive Director of CARB-X and Austin B. Fletcher Professor of Law at Boston University. “Italy’s investment is a powerful addition to the support we receive from a global consortium of funders, including other G7 governments and leading global health foundations. This collective effort underscores the critical importance of international collaboration in the fight against antimicrobial resistance. Together, we are driving innovation and ensuring that the most promising research can be translated into life-saving treatments for patients worldwide.”? ? ?? Read our press release here: bit.ly/3UckAiJ ? #AMR #StopSuperBugs #AntimicrobialResistance #G7 #Medicine #GlobalHealth

An insightful article from IAVI highlights how vaccines can play a pivotal role in combating antimicrobial resistance (AMR). By targeting deadly microbial pathogens, vaccines have the potential to not only save lives but also reduce the reliance on antibiotics – putting a dent in the growing threat of AMR. Read the full article here:?https://lnkd.in/dUpR5hTU #Vaccines #AntimicrobialResistance #Innovation #GlobalHealth

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and CHAI are partnering to tackle gonorrhea infections, including antimicrobial resistance. The partnership will evaluate the clinical needs and address market barriers for gonorrhea screening, preventive, and treatment interventions in low- and middle-income countries (LMICs). “We are excited to embark on this initial body of work with CHAI, leveraging their experience in market assessment and thoughtful implementation of interventions for HIV and other STIs in LMICs over the past 20 years,” said CARB-X Chief of R&D Erin Duffy, PhD. “This collaboration will help us shape impactful strategies to address the growing public health threat posed by AMR, particularly in regions with the highest need," said Dr. David Ripin, CHAI Executive Vice President, Infectious Diseases, Chief Science Officer. Learn more about this partnership: https://ow.ly/3naJ50UfMAj CARB-X Boston University Bundesministerium für Bildung und Forschung Wellcome Trust Biomedical Advanced Research and Development Authority (BARDA) National Institute of Allergy and Infectious Diseases (NIAID) Public Health Agency of Canada | Agence de la santé publique du Canada #Gonorrhea #AntimicrobialResistance #AMR #GlobalAMRInnovationFund

CARB-X is pleased to announce a new partnership with the Clinton Health Access Initiative, Inc.! The partnership will evaluate the clinical needs and address market barriers for diagnostic, preventative, and therapeutic interventions targeting gonorrhea infections in low- and middle-income countries (LMICs). The partnership aims to develop a clear understanding of which solutions to prioritize, implementation hurdles, and how to move toward sustainable markets for AMR-focused interventions in LMICs. Gonorrhea is the second most prevalent sexually transmitted infection (STI) in the world after chlamydia and is caused by the bacterium Neisseria gonorrhoeae (N. gonorrhoeae). Approximately 82 million people around the world are affected by the disease, with the highest prevalence in Africa. Patients with gonorrhea can face serious health effects, including a five-fold increase in HIV transmission, pelvic inflammatory disease, chronic pelvic pain, and infertility. Since patients do not always exhibit symptoms, reported cases may only capture a fraction of the true burden. While gonorrhea is treatable with some antibiotics, the emergence of antibiotic-resistant strains of N. gonorrhea makes treatment more challenging. “We are excited to embark on this initial body of work with CHAI, leveraging their experience in market assessment and thoughtful implementation of interventions for HIV and other STIs in LMICs over the past 20 years,” said CARB-X Chief of R&D Erin Duffy, PhD. “Our goal is to build off work done by others in this space, such as FIND and the Global Antibiotic R&D Partnership (GARDP) and share our learnings broadly so that all entities working toward gonorrhea-focused interventions can provide meaningful solutions where they are needed the most.” ?? Read our press release here: bit.ly/4fWvC3W #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology Pictured below: Kevin Outterson, CARB-X Executive Director, and Dr. David Ripin, CHAI Executive Vice President, Infectious Diseases, Chief Scientific Officer, at the Fourth Global High-Level Ministerial Conference on Antimicrobial Resistance in Jeddah, Kingdom of Saudi Arabia.

??? New interview!? ? CARB-X Chief of Research and Development Erin Duffy, PhD spoke with WuXi AppTec about CARB-X's pivotal work to advance innovative antibacterial products through the development pipeline. She discussed some of the projects CARB-X is supporting and the challenges that are encountered in early drug development in the antimicrobial resistance (AMR) industry. CARB-X launched several Portfolio Acceleration Tools to address these challenges, benefit the larger AMR ecosystem, and accelerate drug development. “We’ve observed common hurdles. One approach could be to address these individually, but we’ve found it more effective to take a proactive approach,” said Dr. Duffy. “Our goal is simple: if we can clear a path for one, we aim to clear it for all.” ?? Read here: bit.ly/3CACbea #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology

CARB-X graduate Pattern Bioscience receives support from Biomedical Advanced Research and Development Authority (BARDA) to further develop its rapid #diagnostic to determine the effectiveness of antibiotics against specific bacteria. Rapid diagnostics are vital for improving the treatment of drug-resistant infections, as current laboratory testing can take days to reach a diagnosis. Faster test results would enable medical staff to treat infections quickly with the appropriate antibiotic.? ? #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology

?? New podcast! CARB-X Chief of External Affairs Damiano de Felice joined the Canadian Antimicrobial Innovation Coalition (CAIC)’s podcast, the AMR Action Podcast, to discuss the Government of #Italy's recent commitment to CARB-X and considerations other governments should prioritize to address antimicrobial resistance (AMR). He spoke about the intersection of innovation and access, emphasizing the importance of collaboration among world leaders and governments to find global solutions to address AMR. ?? Listen here: bit.ly/3ZdXDyg #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology

??? New interview!? ? Kevin Outterson, CARB-X Executive Director and Austin B. Fletcher Professor of Law at Boston University, spoke with Global Health Now, Johns Hopkins Bloomberg School of Public Health’s publication, about how a better business model is needed to prevent the collapse of the antibiotic development pipeline. Investments into push and pull incentives have increased in recent years, but still lag behind necessary levels to bring enough new antibiotics to the market. Prof. Outterson emphasized that antibiotics should be valued based on their benefit to society rather than their volume of sales. ?? Read here: bit.ly/3CFcCsr #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology

Antimicrobial-resistant (AMR) bacteria and fungi are serious health security threats to people in the United States and throughout the world. We provide financial support and technical expertise to develop medical countermeasures that address drug-resistant secondary infections with the goal of regulatory approval and potential procurement. This approach helps bolster national security and protects people from the health consequences that could occur following a chemical, biological, radiological, or nuclear (CBRN) incident. This U.S. Antibiotic Awareness Week (#USAAW), learn more about our efforts to combat AMR and the partnerships that make it happen: https://ow.ly/k1Eq50U8f6c To learn more about our recent AMR work, including ways to partner with us, visit: https://ow.ly/wZia50U8f6b

Exciting News! ?? We're proud to announce the extension of funding from CARB-X supporting the preclinical development of Debio 1453, our anti-gonorrhoea program. We perceive these newly awarded $5.76 million USD as a recognition of our efforts combating the threat of antimicrobial resistance. ?? Read more in our latest press release: https://lnkd.in/eXDPs75t #antimicrobialresistance #globalhealth #drugresistance #antibiotics